

Tovetumab

Chemical Properties

CAS No. :	1243266-04-7
Formula:	
Molecular Weight:	144.78 kDa
Storage:	Store at low temperature -20°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>

Biological Description

Description	Tovetumab (MEDI-575) is a fully human monoclonal antibody that exhibits high selectivity for platelet-derived growth factor receptor alpha (PDGFR α). It functions by specifically inhibiting PDGFR α signal transduction pathways, and it is currently being utilized in clinical research for the treatment of aggressive malignancies including glioblastoma and non-small cell lung cancer (NSCLC).
Targets(IC50)	PDGFR
In vitro	Methods: MG-63 cells were treated with Tovetumab (0.001-10 nM, 10 minutes), and the expression of related proteins was detected by Western blot. Results: Tovetumab was able to inhibit ligand-induced phosphorylation of human PDGFR α in MG-63 cells. [2]
In vivo	Methods: Tovetumab (0.6, 6.0, 60 mg/kg, intravenous injection) was administered to cynomolgus monkeys to observe its effects. Results: Tovetumab induced a more than 100-fold increase in circulating platelet-derived growth factor (PDGF-AA) levels in cynomolgus monkeys. [1]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.0069 mL	0.0345 mL	0.0691 mL
5 mM	0.0014 mL	0.0069 mL	0.0138 mL
10 mM	0.0007 mL	0.0035 mL	0.0069 mL
50 mM	0.0001 mL	0.0007 mL	0.0014 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481